Institut Català de la Salut
[Mínguez-Olaondo A] Neurology Department, Hospital Universitario Donostia, San Sebastián, Spain. Athenea Neuroclinics, Policlínica Guipúzcoa, Grupo Quirón Salud Donostia, San Sebastián, Spain. Neuroscience Area, Biodonostia Health Institute, Donostia, Spain. Medicine Faculty, University of Deusto, Bilbao, Spain. Clínica Universidad de Navarra, Pamplona, Spain. [Quintas S] Hospital Universitario de la Princesa, Madrid, Spain. [Morollón Sánchez-Mateos N] Headache and Neuralgia Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [López-Bravo A] Hospital Reina Sofía, Tudela, Spain. Instituto de Investigación Sanitaria Aragón, Zaragoza, Spain. [Vila-Pueyo M] Grup de Recerca en Cefalea i Dolor Neurològic, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Grozeva V] Private Neurology Practice, Sofia, Bulgaria
Vall d'Hebron Barcelona Hospital Campus
2022-07-20T10:12:16Z
2022-07-20T10:12:16Z
2022-01
Cutaneous allodynia; Risk factors; Treatment
Alodinia cutánea; Factores de riesgo; Tratamiento
Alodínia cutània; Factors de risc; Tractament
Objective: In the present work, we conduct a narrative review of the most relevant literature on cutaneous allodynia (CA) in migraine. Background: CA is regarded as the perception of pain in response to non-noxious skin stimulation. The number of research studies relating to CA and migraine has increased strikingly over the last few decades. Therefore, the clinician treating migraine patients must recognize this common symptom and have up-to-date knowledge of its importance from the pathophysiological, diagnostic, prognostic and therapeutic point of view. Methods: We performed a comprehensive narrative review to analyze existing literature regarding CA in migraine, with a special focus on epidemiology, pathophysiology, assessment methods, risk for chronification, diagnosis and management. PubMed and the Cochrane databases were used for the literature search. Results: The prevalence of CA in patients with migraine is approximately 60%. The mechanisms underlying CA in migraine are not completely clarified but include a sensitization phenomenon at different levels of the trigemino-talamo-cortical nociceptive pathway and dysfunction of brainstem and cortical areas that modulate thalamocortical inputs. The gold standard for the assessment of CA is quantitative sensory testing (QST), but the validated Allodynia 12-item questionnaire is preferred in clinical setting. The presence of CA is associated with an increased risk of migraine chronification and has therapeutic implications. Conclusions: CA is a marker of central sensitization in patients with migraine that has been associated with an increased risk of chronification and may influence therapeutic decisions.
Article
Versió publicada
Anglès
Migranya - Complicacions; Pell - Malalties; DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Headache Disorders::Headache Disorders, Primary::Migraine Disorders; Other subheadings::Other subheadings::Other subheadings::/complications; ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos con cefaleas::cefaleas primarias::trastornos migrañosos; Otros calificadores::Otros calificadores::Otros calificadores::/complicaciones
Frontiers Media
Frontiers in Neurology;12
https://doi.org/10.3389/fneur.2021.831035
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1655]